日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer

卡铂、吉西他滨和米非司酮用于治疗晚期乳腺癌和复发/持续性上皮性卵巢癌

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-025-07783-7
Stringer-Reasor, Erica M; Saha, Poornima; Kocherginsky, Masha; Lastra, Ricardo; Baker, Gabrielle; Lenygel, Ernst; Karrison, Theodore; Olalde, Lauren; Mokrzycki, Elizabeth; Hahn, Olwen M; Hoffman, Philip C; Conzen, Suzanne D; Fleming, Gini F; Nanda, Rita
肿瘤
肿瘤免疫
乳腺癌
卵巢癌
发表日期：2025
文献求助 收藏

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

CDKN2A功能缺失可预测非小细胞肺癌的免疫治疗耐药性

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-021-99524-1
Gutiontov, Stanley I; Turchan, William Tyler; Spurr, Liam F; Rouhani, Sherin J; Chervin, Carolina Soto; Steinhardt, George; Lager, Angela M; Wanjari, Pankhuri; Malik, Renuka; Connell, Philip P; Chmura, Steven J; Juloori, Aditya; Hoffman, Philip C; Ferguson, Mark K; Donington, Jessica S; Patel, Jyoti D; Vokes, Everett E; Weichselbaum, Ralph R; Bestvina, Christine M; Segal, Jeremy P; Pitroda, Sean P
肺癌
肿瘤
肿瘤免疫
治疗耐药
CDKN2A
细胞生物学
免疫/内分泌
发表日期：2021
文献求助 收藏

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

全面的基因检测可以识别出大多数非小细胞肺癌患者（特别是腺癌患者）体内可靶向的基因组改变，这是一项单中心研究的结果。

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.7739
Vigneswaran, Janani; Tan, Yi-Hung Carol; Murgu, Septimiu D; Won, Brian M; Patton, Kathryn Alexa; Villaflor, Victoria M; Hoffman, Philip C; Hensing, Thomas; Hogarth, D Kyle; Malik, Renuka; MacMahon, Heber; Mueller, Jeffrey; Simon, Cassie A; Vigneswaran, Wickii T; Wigfield, Christopher H; Ferguson, Mark K; Husain, Aliya N; Vokes, Everett E; Salgia, Ravi
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

一项随机 I 期临床试验，研究纳米颗粒白蛋白结合型紫杉醇联合或不联合米非司酮治疗晚期乳腺癌的疗效

期刊:Springerplus
影响因子:
doi:10.1186/s40064-016-2457-1
Nanda, Rita; Stringer-Reasor, Erica M; Saha, Poornima; Kocherginsky, Masha; Gibson, Jean; Libao, Bernadette; Hoffman, Philip C; Obeid, Elias; Merkel, Douglas E; Khramtsova, Galina; Skor, Maxwell; Krausz, Thomas; Cohen, Ronald N; Ratain, Mark J; Fleming, Gini F; Conzen, Suzanne D
肿瘤
肿瘤免疫
乳腺癌
发表日期：2016
文献求助 收藏

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

在既往接受过治疗的非小细胞肺癌患者中，一项随机 II 期试验评估了一种新型皮疹评分量表和血清蛋白质组学预测因子，该试验比较了序贯或同步使用西妥昔单抗和培美曲塞的疗效。

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-14-5
Maitland, Michael L; Levine, Matthew R; Lacouture, Mario E; Wroblewski, Kristen E; Chung, Christine H; Gordon, Ilyssa O; Szeto, Livia; Ratko, Gail; Soltani, Keyoumars; Kozloff, Mark F; Hoffman, Philip C; Salgia, Ravi; Carbone, David P; Karrison, Theodore G; Vokes, Everett E
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2014
文献求助 收藏

Phase II trial of temsirolimus in patients with metastatic breast cancer.

替西罗莫司治疗转移性乳腺癌患者的 II 期试验

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-011-1910-7
Fleming Gini F, Ma Cynthia X, Huo Dezheng, Sattar Husain, Tretiakova Maria, Lin L, Hahn Olwen M, Olopade F O, Nanda R, Hoffman Philip C, Naughton M J, Pluard Timothy, Conzen Suzanne D, Ellis Matthew J
肿瘤
乳腺癌
发表日期：2012
文献求助 收藏

Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer

一项针对III期非小细胞肺癌的诱导化疗联合伊立替康、卡铂和紫杉醇同步放化疗的I期研究

期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1097/JTO.0b013e31815e8566
Choong, Nicholas W; Vokes, Everett E; Haraf, Daniel J; Tothy, Peter K; Ferguson, Mark K; Kasza, Kristen; Rudin, Charles M; Hoffman, Philip C; Krauss, Stuart A; Szeto, Livia; Mauer, Ann M
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2008
文献求助 收藏

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer

厄洛替尼联合多模式疗法治疗不可手术的III期非小细胞肺癌的I期临床试验

期刊:Journal of Thoracic Oncology
影响因子:20.8
doi:10.1097/JTO.0b013e31818396a4
Choong, Nicholas W; Mauer, Ann M; Haraf, Daniel J; Lester, Eric; Hoffman, Philip C; Kozloff, Mark; Lin, Shang; Dancey, Janet E; Szeto, Livia; Grushko, Tatyana; Olopade, Olufunmilayo I; Salgia, Ravi; Vokes, Everett E
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2008
文献求助 收藏